Resistance acquisition to MDM2 inhibitors
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Various experimental strategies aim to (re)activate p53 signalling in cancer cells. The most advanced clinically are small-molecule inhibitors of the autoregulatory interaction between p53 and MDM2 (murine double minute 2). Different MDM2 inhibitors are currently under investigation in clinical trials. As for other targeted anti-cancer therapy approaches, relatively rapid resistance acquisition may limit the clinical efficacy of MDM2 inhibitors. In particular, MDM2 inhibitors were shown to induce p53 mutations in experimental systems. In the present article, we summarize what is known about MDM2 inhibitors as anti-cancer drugs with a focus on the acquisition of resistance to these compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is important to note, that, because of the nature of GBM tumor vasculature, which was shown to comprise between 30–50% of poorly perfused vessels [35], we cannot exclude the possibility of a contribution from intravascular drug and blood in our brain tissue AUCs calculations.”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [35]
In the citing paper
“Of note, acquired TP53 mutation is a key mechanism of resistance to MDM2 inhibition in vitro.31”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [31]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395
Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors
Zhao, Y., Liu, L., Sun, W., Lu, J., McEachern, D., Li, X., Yu, S., Bernard, D., Ochsenbein, P., Ferey, V., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3125417 · Cited by 234
Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190
Self-citationHDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Stühmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R. A., Daniel, P. T., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1489 · Cited by 180
Parks, D. J., LaFrance, L. V., Calvo, R. R., Milkiewicz, K. L., Gupta, V., Lattanze, J., Ramachandren, K., Carver, T. E., Petrella, E. C., Cummings, M. D., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.009 · Cited by 167
Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction
Rew, Y., Sun, D., Gonzalez-Lopez De Turiso, F., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Deignan, J., Fox, B. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300354j · Cited by 165
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163
Recent Advances in the Therapeutic Perspectives of Nutlin-3
Secchiero, P., Bosco, R., Celeghini, C., & Zauli, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222586 · Cited by 158
Reactivation of p53: from peptides to small molecules
Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 149
Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 148
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Yuan, Y., Liao, Y.-M., Hsueh, C.-T., & Mirshahidi, H. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-16 · Cited by 131
Therapeutic exploitation of the p53 pathway
Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127
Van Maerken, T., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J., Cuvelier, C. A., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp355 · Cited by 121
Self-citationTargeting p53 by small molecules in hematological malignancies
Saha, M. N., Qiu, L., & Chang, H. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-23 · Cited by 112
Michaelis, M., Rothweiler, F., Klassert, D., von Deimling, A., Weber, K., Fehse, B., Kammerer, B., Doerr, H. W., & Cinatl, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1856 · Cited by 100
Self-citationIsoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction
Hardcastle, I. R., Ahmed, S. U., Atkins, H., Calvert, H., Curtin, N. J., Farnie, G., Golding, B. T., Griffin, R. J., Guyenne, S., Hutton, C., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.061 · Cited by 94
Self-citationYang, J., Ahmed, A., Poon, E., Perusinghe, N., de Haven Brandon, A., Box, G., Valenti, M., Eccles, S., Rouschop, K., Wouters, B., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00959-08 · Cited by 85
Nongenotoxic p53 Activation Protects Cells against S-Phase–Specific Chemotherapy
Kranz, D., & Dobbelstein, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1527 · Cited by 84
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Valentine, J. M., Kumar, S., & Moumen, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-79 · Cited by 77
Furet, P., Chêne, P., Pover, A. D., Stachyra, T., Lisztwan, J. H., Kallen, J. A., & Masuya, K. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.083 · Cited by 74
Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics
Lee, A. J. X., & Swanton, C. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.008 · Cited by 71
Rao, B., Laín, S., & Thompson, A. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.702 · Cited by 67
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)
Zak, K., Pecak, A., Rys, B., Wladyka, B., Dömling, A., Weber, L., Holak, T. A., & Dubin, G. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.765405 · Cited by 65
Tabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1101 · Cited by 64
Shen, H., Moran, D. M., & Maki, C. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1901 · Cited by 61
Jones, R. J., Bjorklund, C. C., Baladandayuthapani, V., Kuhn, D. J., & Orlowski, R. Z. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0135 · Cited by 58
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
Chen, L., & Tweddle, D. A. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00173 · Cited by 47
Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W., & Giardina, C. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.20795 · Cited by 45
Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)
Weber, L. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903514129 · Cited by 44
Molecular Mimicry-Based Repositioning of Nutlin-3 to Anti-Apoptotic Bcl-2 Family Proteins
Ha, J., Won, E.-Y., Shin, J., Jang, M. K., Ryu, K., Bae, K., Park, S. G., Park, B. C., Yoon, H. S., & Chi, S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja109521f · Cited by 43
Wang, W., Shangguan, S., Qiu, N., Hu, C., Zhang, L. J., & Hu, Y. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.061 · Cited by 37
Blackburn, T. J., Ahmed, S. U., Coxon, C. R., Liu, J., Lü, X., Golding, B. T., Griffin, R. J., Hutton, C., Newell, D. R., Ojo, O. S., et al. (2013) · MedChemComm · doi:10.1039/c3md00161j · Cited by 30
Self-citationZhang, F., Throm, S. L., Murley, L. L., Miller, L. A., Zatechka, D. S., Guy, R. K., Kennedy, R. M., & Stewart, C. F. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.024 · Cited by 28
In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
Wei, S. J., Joseph, T., Sim, A. Y. L., Yurlova, L., Zolghadr, K., Lane, D., Verma, C., & Ghadessy, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062564 · Cited by 28
Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program
Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., Keir, S. T., Morton, C. L., Reynolds, C. P., Kang, M. H., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.23319 · Cited by 26
Michaelis, M., Rothweiler, F., Agha, B., Barth, S., Voges, Y., Löschmann, N., von Deimling, A., Breitling, R., Wilhelm Doerr, H., Rödel, F., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.35 · Cited by 22
Self-citationProtecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
Cited by
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & Müller, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 291
The role of DNA damage responses in p53 biology
Speidel, D. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1459-z · Cited by 160
Self-citationVerreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Deng, M., Zhang, L., Zheng, W., Chen, J., Du, N., Li, M., Chen, W., Huang, Y., Zeng, N., Song, Y., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02586-w · Cited by 116
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106
Metadata
- Authors
- Cinatl, J., Speidel, D., Hardcastle, I., & Michaelis, M.
- Affiliations
- Goethe University Frankfurt (DE)
- The University of Sydney (AU)
- Newcastle University (GB)
- University of Kent (GB)
- Corresponding author
- Cinatl, Jindrich
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2014-08-01
- Volume
- 42
- Issue
- 4
- Pages
- 752-757
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2062745242
- Cited by
- 30
- References
- 50
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 2
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- MDM2 inhibitors, drug resistance, p53, p53-MDM2 interaction, TP53 mutation, small molecule inhibitors, cancer therapy, targeted therapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Signal Transduction, Tumor Suppressor Protein p53, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.